Sucampo licenses R-Tech Ueno's ophthalmic drug Rescula; later returns rights
Executive Summary
Sucampo Pharmaceuticals' Sucampo Pharma Americas division licensed exclusive rights to Tokyo biotech R-Tech Ueno's (RTU) Rescula (unoprostone isopropyl) eye drops, and related intellectual property, in the US and Canada for open-angle glaucoma and ocular hypertension. The deal includes rights to develop the marketed synthetic docosanoid for additional therapeutic uses, as well as the right of first refusal to sell unoprostone isopropyl in the US and Canada for any indications developed by RTU.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice